GLP-1s and Pregnancy: The Research Is Still In Its Infancy

Nearly 25 million US women aged 18-44 years — almost half of all women of reproductive age — are eligible for GLP-1 medications . More than 40% of all pregnancies in this country are unplanned . Combined, these statistics take the reproductive health implications of the popular drugs beyond OB/GYN care and fertility clinics into primary care. Here’s what experts and new consensus guidelines say about how to navigate GLP-1 treatment during patients’ childbearing years. Before Prescribing: Assess Risk, Goals, and Pregnancy Plans The patients at highest risk for an unplanned pregnancy while on a GLP-1 are those with substantial metabolic burden and/or ovulatory dysfunction — particularly people with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome ( PCOS ), who may resume regular cycles as their metabolic health improves. “Being at a higher BMI is associated with things like insulin resistance, sleep apnea, and hypertension,” said Christina Boots, MD, reproductive endocrinologist at Northwestern Medicine in Chicago, and co-author of a narrative review on obesity, GLP-1 medications, and reproductive health . Those conditions all have links to fertility issues. “So even if it’s not severe, maybe GLP-1s are having subtle effects on uterine perfusion and inflammation and other things.” When prescribing a GLP-1 to a patient of childbearing age, a thorough intake should include a discussion of reproductive health: Ask whether the patient is hoping to get pregnant soon, later, or not at all. Discuss menstrual regularity, signs of anovulation, and possible history of PMOS — or, if the patient has been pregnant before, gestational diabetes, preeclampsia, or other adverse pregnancy outcomes. Ask about infertility history or fertility treatment plans because age or a delayed referral can affect a patient’s options. Review the patient’s current contraception and flag the risk for missed doses due to GLP-1-related vomiting or diarrhea. Contraception and Preconception Planning The guidance here depends on where a patient falls on her reproductive timeline. “If they’re on these medications and they’re not trying to conceive, get them on contraception. There’s no reason not to, and then it’s a nonissue,” said Stacey Ehrenberg, MD, director of Diabetes in Pregnancy at the Cleveland Clinic in Cleveland. “If they are trying to conceive, then involve the obstetric team and the maternal-fetal medicine team and the dietitian team early, so that when they become pregnant, there’s a seamless transition.” An important note about pregnancy prevention: GI side effects such as vomiting, which often accompanies GLP-1 medications, may compromise the reliability of oral contraceptives. Separately, tirzepatide in particular has been found to reduce the pill’s bioavailability. Patients experiencing significant GI side effects or taking tirzepatide should either switch to a non-oral contraceptive or add a barrier method after starting a GLP-1 and after each dose increase . When a patient does want to conceive in the near future, make sure they understand these drugs have not been proven safe in pregnancy. They’ll have to stop the GLP-1 at some point. Semaglutide labeling puts the timing at 2 months before a planned pregnancy, based on the drug’s long half-life. But the new consensus guidelines say evidence doesn’t support a universal washout period — they recommend discontinuing use of any GLP-1 only after a patient learns she’s pregnant. Stop too soon, and the loss of metabolic benefits may interfere with conception. “I’ve seen patients who were like, ‘Okay, I’m stopping my meds Jan. 1,’ and then they don’t get pregnant,” Boots said. “By April they’ve gained 20 pounds back because they weren’t supported, and they’re pretty distressed about one, having some delayed conception, but also because they’ve gained the weight back, and now they’re not cycling as well.” That timing is a highly individualized decision and should be guided by age and cycle regularity. Boots advised considering how likely a patient is to get pregnant in each cycle — in her early thirties, it’s likely to happen within 6 months. Paired with counseling about how to manage weight regain, that makes her a good candidate to stop sooner rather than later. “But if she’s 42 years old, doesn’t cycle regularly, and has prediabetes, perhaps she should stay on the GLP-1 longer,” Boots said. Six months of treatment could optimize her health to the point where pregnancy without intervention becomes possible. At Pregnancy: Stop, Reassure, and Bridge Care No large-scale studies have looked at the effects of GLP-1 use during pregnancy, so current guidance doesn’t support intentional use. But limited observational data on inadvertent early exposure have shown no increased risk to the fetus . This means a positive pregnancy test should prompt discontinuation and follow-up — not alarm. If a patient stops in the first month of pregnancy, standard prenatal growth monitoring should be enough, Ehrenberg said. Enroll her in the drugmaker’s pregnancy exposure registry and refer her to a maternal-fetal medicine specialist with expertise in managing pregnancies in people with obesity or diabetes. Depending on the patient, she may need close monitoring for gestational diabetes . For patients using a GLP-1 to manage existing diabetes, a more urgent risk emerges when the drug is stopped. Glucose levels can rise quickly. “You want to make sure they have a really tight follow-up with maternal-fetal medicine or endocrinology,” Ehrenberg said. “You need to get them in very quickly, so there’s not a large gap.” Even when the drug is prescribed for obesity or related comorbidities, discontinuation needs support. More referrals may be called for. “When you stop a GLP-1, most people get weight regain. And most people gain weight when they get pregnant,” Boots said. She recommends referring patients to a dietitian to make sure they’re eating a healthy pregnancy diet, and perhaps a mental health professional as well, “to help them cope with the guilt and disappointment that comes as weight is gained, especially after they’ve worked so hard on it.” Postpartum: A Promising, Unproven Prevention Window Postpartum prescriptions for GLP-1 medications have risen dramatically, to the point where they may have outpaced the research. Optimal timing, lactation safety, and long-term health outcomes remain open questions. But this period could become an important opportunity for GLP-1-based cardiometabolic prevention, especially in women who experience gestational diabetes or preeclampsia. Both conditions carry outsized long-term risk. “There are very few fields where a patient’s cardiometabolic trajectory completely changes within 9 months,” said Zainab Mahmoud, MD, assistant professor of both cardiology and OB/GYN at Washington University in St. Louis. She’s co-author of a recent review on the role of GLP-1 medications in maternal cardiometabolic health . “A patient can go into pregnancy at a normal weight and come out of pregnancy with either overweight or obesity, and that will be a different trajectory for her for the rest of her life.” Early data suggest postpartum GLP-1 therapy may improve glycemic parameters among people with prior gestational diabetes. For women who experienced preeclampsia, it may reduce the risk for later cardiovascular disease, though it’s too soon to tell. “We don’t have the data to know the effect,” Mahmoud said. “But if an individual patient has another indication for GLP-1 and had preeclampsia during pregnancy, it’s reasonable to have that conversation and think about prescribing it.” When it comes to GLP-1s during breastfeeding, safety data are scant, but what exists suggests it may be safe . Decisions should balance the benefits of breastfeeding for both mother and child against the theoretical risk for infant exposure. If a GLP-1 is used during lactation, the consensus calls for close attention to maternal nutrition, hydration, micronutrient status, infant growth, and developmental milestones. Mahmoud reported receiving grant funding from the National Heart, Lung, and Blood Institute. No other authors reported having disclosures.